Holen Sie sich die Stockscreener-App
2.10
0.47%
-0.010
Vorhandelsmarkt:
2.10
Silexion Therapeutics Corp Aktie (SLXN) Neueste Nachrichten
Silexion outlines 2026 plans after transformational 2025 progress - TipRanks
Silexion Therapeutics Corp Highlights 2025 Achievements and 2026 Milestones - TradingView — Track All Markets
Silexion Therapeutics' Cancer Drug to Enter Human Trials in Early 2026 - MarketScreener
Silexion Therapeutics Reports Promising Preclinical Results for SIL204 in KRAS-Driven Cancers and Plans Phase 2/3 Trial Initiation for 2026 - Quiver Quantitative
Silexion Therapeutics Releases CEO Letter to Shareholders - GlobeNewswire
Merger Talk: Is Silexion Therapeutics Corp Equity Warrant stock trading at a premium valuation2025 Top Decliners & Daily Volume Surge Signals - moha.gov.vn
Can Silexion Therapeutics Corp Equity Warrant stock beat market expectations this quarterJuly 2025 Patterns & Fast Exit and Entry Trade Guides - Улправда
Can Silexion Therapeutics Corp Equity Warrant stock hit analyst price targetsJuly 2025 Retail & Free Technical Pattern Based Buy Signals - Улправда
Can Silexion Therapeutics Corp Equity Warrant stock hit record highs againJuly 2025 Weekly Recap & Daily Chart Pattern Signal Reports - Улправда
Will Silexion Therapeutics Corp Equity Warrant stock pay special dividendsTrade Exit Report & Weekly Top Performers Watchlists - DonanımHaber
How Silexion Therapeutics Corp stock compares to growth peersQuarterly Performance Summary & Free Real-Time Market Sentiment Alerts - DonanımHaber
Will Silexion Therapeutics Corp Equity Warrant stock reach Wall Street targetsJuly 2025 Technicals & Growth-Oriented Investment Plans - Улправда
Risk Analysis: Can Silexion Therapeutics Corp Equity Warrant stock hit analyst price targetsPortfolio Risk Report & High Conviction Trade Alerts - Улправда
Treasury Yields: How strong is Silexion Therapeutics Corp stock revenue growthWeekly Trade Report & AI Based Buy and Sell Signals - DonanımHaber
How strong is Silexion Therapeutics Corp stock revenue growthMarket Trend Summary & Real-Time Volume Spike Alerts - DonanımHaber
Silexion Therapeutics (NASDAQ:SLXN) Upgraded at Zacks Research - Defense World
Can Silexion Therapeutics Corp stock sustain free cash flow growth2025 Year in Review & Fast Exit/Entry Strategy Plans - Улправда
Gains Report: Will Silexion Therapeutics Corp Equity Warrant stock reach Wall Street targetsJuly 2025 Recap & AI Driven Stock Price Forecasts - Улправда
Stop Loss: Can Silexion Therapeutics Corp Equity Warrant stock hit record highs again - Улправда
Stock Recap: Will Silexion Therapeutics Corp Equity Warrant stock reach Wall Street targetsIPO Watch & Daily Profit Maximizing Trade Tips - Улправда
Silexion Therapeutics submits Phase 2/3 trial application - MSN
Silexion Therapeutics Submits Phase 2/3 Trial Application - TipRanks
Silexion submits Phase 2/3 trial application to Israel for SIL204 - TipRanks
Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 - TradingView — Track All Markets
Silexion Therapeutics Advances Regulatory Submission for Phase 2/3 Trial of SIL204 in Pancreatic Cancer - Quiver Quantitative
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for Sil204 in Locally Advanced Pancreatic Cancer - marketscreener.com
Silexion Therapeutics (NASDAQ:SLXN) Now Covered by Litchfield Hills Research - Defense World
Silexion Therapeutics Announces Submission of Phase 2/3 - GlobeNewswire
Silexion Therapeutics initiated with a buy at Litchfield Hills - MSN
Silexion Therapeutics initiated with a Buy at Litchfield Hills - TipRanks
Bearish Setup: Is Silexion Therapeutics Corp Equity Warrant stock recession proof2025 Momentum Check & AI Forecasted Entry/Exit Points - moha.gov.vn
Silexion Shares Decline After Update on German Regulatory Review - MSN
Silexion Therapeutics (SLXNW) Stock Analysis Report | Financials & Insights - Benzinga
How buybacks impact Silexion Therapeutics Corp stock valueProfit Target & Intraday High Probability Setup Alerts - Newser
Buy Recommendation for Silexion Therapeutics: Promising Developments and Market Potential in Pancreatic Cancer Treatment - TipRanks
Silexion Therapeutics drops 18%, prices $5M share offering - MSN
Silexion receives positive feedback from German Health Authority for SIL204 - TipRanks
Silexion Therapeutics (SLXN) Stock Analysis Report | Financials & Insights - Benzinga
Silexion stock falls after receiving German regulatory feedback By Investing.com - Investing.com Canada
Silexion stock falls after receiving German regulatory feedback - Investing.com
Silexion Therapeutics receives positive feedback from German health authority on design of phase 2/3 clinical trial - marketscreener.com
Silexion Therapeutics Gains Positive Feedback for SIL204 Trial - TipRanks
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer - The Manila Times
How Silexion Therapeutics Corp Equity Warrant stock reacts to Fed rate cuts2025 Buyback Activity & Weekly Stock Breakout Alerts - Newser
Aug Mood: Can Silexion Therapeutics Corp Equity Warrant stock sustain free cash flow growthJuly 2025 Catalysts & Consistent Profit Trade Alerts - moha.gov.vn
SLXNSilexion Therapeutics Corp Latest Stock News & Market Updates - Stock Titan
Its Stock Has Paid Off Big Time For Silexion Therapeutics Corp - setenews.com
Silexion Therapeutics completes toxicology studies for SIL204 - MSN
Silexion stock jumps after toxicology studies show no systemic toxicity - MSN
Silexion Completes Toxicology Studies For SIL204; Phase 2/3 Pancreatic Cancer Trial To Begin In Q2 - Nasdaq
Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference - marketscreener.com
Silexion stock jumps after toxicology studies show no systemic toxicity By Investing.com - Investing.com Canada
Silexion to begin phase 2/3 pancreatic cancer clinical trial in Q2 2026 - marketscreener.com
Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026 - TradingView
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):